Literature DB >> 31840418

Bone marrow as a target and accomplice of vascular complications in diabetes.

Marianna Santopaolo1, Maria Sambataro2, Gaia Spinetti3, Paolo Madeddu1.   

Abstract

Peripheral vascular complications are common in diabetic patients. While pathogenic mechanisms have received much consideration, only recently regenerative processes captured attention. There is now a consensus that the bone marrow is a source of reparative cells and that this healing mechanism is lost in people with diabetes, especially in those suffering from ischemic complications. This failure was thought to occur due to a negative impact of diabetes on the mobilization of stem/progenitor cells with angiogenic properties from the bone marrow to the circulation. Moreover, those patients showing severely reduced bone marrow cell mobilization also bared a very high risk for adverse cardiovascular events. More recently, the structural integrity of the bone marrow was recognized to be altered because of the rarefaction of local microvasculature and innervation, thus mirroring anatomical features that typically occur in peripheral tissues. Ensuing hypoxia, nutrient starvation, and creation of an acidic and oxidative environment concur in causing the depletion of stem/progenitor cells in the endosteal niche and in forcing stromal cells to activate an adipogenesis program. Moreover, stem/progenitor cells acquire a pathogenic phenotype and, once mobilized, can pass harmful signalling molecules to vascular cells of peripheral tissues thereby contributing to ischemic complications. These new pieces of evidence indicate that the bone marrow should deserve more attention in the current care of critical limb ischemia and diabetic foot. Owing to powerful reserve capacities, the bone marrow integrity could be preserved and even rescued using rehabilitation programs and pharmacological treatments with consequent benefit for local and whole-organism homeostasis.
© 2019 John Wiley & Sons, Ltd.

Entities:  

Keywords:  bone marrow; diabetes; ischemia; microangiopathy; stem cells

Year:  2019        PMID: 31840418     DOI: 10.1002/dmrr.3240

Source DB:  PubMed          Journal:  Diabetes Metab Res Rev        ISSN: 1520-7552            Impact factor:   4.876


  6 in total

Review 1.  When a Friend Becomes Your Enemy: Natural Killer Cells in Atherosclerosis and Atherosclerosis-Associated Risk Factors.

Authors:  Maria Teresa Palano; Martina Cucchiara; Matteo Gallazzi; Federica Riccio; Lorenzo Mortara; Gian Franco Gensini; Gaia Spinetti; Giuseppe Ambrosio; Antonino Bruno
Journal:  Front Immunol       Date:  2022-01-13       Impact factor: 7.561

Review 2.  The Immune-Centric Revolution in the Diabetic Foot: Monocytes and Lymphocytes Role in Wound Healing and Tissue Regeneration-A Narrative Review.

Authors:  Laura Rehak; Laura Giurato; Marco Meloni; Andrea Panunzi; Giada Maria Manti; Luigi Uccioli
Journal:  J Clin Med       Date:  2022-02-08       Impact factor: 4.241

Review 3.  Practical Considerations for Translating Mesenchymal Stromal Cell-Derived Extracellular Vesicles from Bench to Bed.

Authors:  Pauline Po Yee Lui; Yung Tim Leung
Journal:  Pharmaceutics       Date:  2022-08-12       Impact factor: 6.525

Review 4.  Impact of Diabetes Mellitus on the Potential of Autologous Stem Cells and Stem Cell-Derived Microvesicles to Repair the Ischemic Heart.

Authors:  Gemma Vilahur; Phuong Hue Nguyen; Lina Badimon
Journal:  Cardiovasc Drugs Ther       Date:  2021-07-12       Impact factor: 3.947

Review 5.  When Good Guys Turn Bad: Bone Marrow's and Hematopoietic Stem Cells' Role in the Pathobiology of Diabetic Complications.

Authors:  Maria Cristina Vinci; Elisa Gambini; Beatrice Bassetti; Stefano Genovese; Giulio Pompilio
Journal:  Int J Mol Sci       Date:  2020-05-29       Impact factor: 5.923

6.  Diabetic foot disease: "The Times They are A Changin' ".

Authors:  Sicco A Bus; Jaap J van Netten; Matilde Monteiro-Soares; Benjamin A Lipsky; Nicolaas C Schaper
Journal:  Diabetes Metab Res Rev       Date:  2020-03       Impact factor: 4.876

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.